Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202503281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Nok Yin Tam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, RNAi Therapeutics, Ribonucleoproteins, Ribonucleoproteins, Small Nuclear. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
RNAi therapeutics can potentially address undruggable diseases. However, their full potential is stymied by delivery challenges. An siRNA delivery platform by remodeling the human U4 small nuclear ribonucleoprotein complex (snRNP) is developed. This remodeled protein‐siRNA complex (SmiRNP) serves as a biocompatible, modular, and customizable platform for attaching desired functional modules to overcome delivery hurdles. Here, it is demonstrated that the SmiRNP complex, by using siRNA against KRAS as a proof of principle, can deliver the siRNA into cells and protect it from nuclease degradation, allowing the siRNA to knockdown KRAS mRNA and protein levels, reduce cancer cell viability, and suppress tumor growth in vivo. This general strategy allows many more modular combinations and would enable the delivery of a wide spectrum of RNAi therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China.
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China.
- State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
ORCID-Profile: Wei Shen Aik
Zitieren
APA
Tam, N. Y., Wang, X., Chan, G. C. Y., Kong, W. P., Chau, W. Y., Fu, X., Wong, K. Y., Lung, H. L., Yu, Z. L., & Aik, W. S. (2025). Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503281
Vancouver
Tam NY, Wang X, Chan GCY, Kong WP, Chau WY, Fu X, et al. Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202503281
BibTeX
@article{Tam2025,
author = {Tam, Nok Yin and Wang, Xiaoqi and Chan, Grace Chung Yan and Kong, Wai Po and Chau, Wai Yin and Fu, Xiuqiong and Wong, Kwok-Yin and Lung, Hong Lok and Yu, Zhi-Ling and Aik, Wei Shen},
title = {Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202503281}
}
EUVIMED